Cancer Research AMC Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chavez-Reyes, A.
Right arrow Articles by Lozano, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chavez-Reyes, A.
Right arrow Articles by Lozano, G.
[Cancer Research 63, 8664-8669, December 15, 2003]
© 2003 American Association for Cancer Research

Regular Articles

Switching Mechanisms of Cell Death in mdm2- and mdm4-null Mice by Deletion of p53 Downstream Targets

Arturo Chavez-Reyes12, John M. Parant1, Lisa L. Amelse1, Roberto Montes de Oca Luna2, Stanley J. Korsmeyer3 and Guillermina Lozano1

1 Department of Molecular Genetics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas;
2 Department of Microbiology and Immunology, School of Biological Sciences, Universidad Autónoma de Nuevo León, Monterrey, Mexico; and
3 Departments of Pathology and Medicine, Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The p53 tumor suppressor ensures maintenance of genome integrity by initiating either apoptosis or cell cycle arrest in response to DNA damage. Deletion of either mdm2 or mdm4 genes, which encode p53 inhibitors, results in embryonic lethality. The lethal phenotypes are rescued in the absence of p53, which indicates that increased activity of p53 is the cause of lethality in the mdm2- and mdm4-null embryos. Here we show that mdm2-null embryos die because of apoptosis initiated at 3.5 days postcoitum (dpc). Partial rescue of mdm2-null embryos by deletion of bax allows survival to 6.5 dpc and alters the mechanism of death from apoptosis to cell cycle arrest, indicating that bax is a critical component of the p53 pathway in early embryogenesis. The death of mdm4-null embryos is due to p53-initiated cell cycle arrest at 7.5 dpc. Deletion of p21(p21waf1/cip1), a p53 downstream target partially responsible for cell cycle arrest, does not rescue this phenotype; however, deletion of p21 alters the mechanism of cell death from lack of proliferation to apoptosis. Thus, in both examples, deletion of a p53 downstream target gene allows p53 to redirect its efforts, highlighting a high degree of plasticity in p53 function.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
p53 maintains genome integrity in response to DNA-damaging agents such as UV radiation (1) , {gamma} radiation (2 , 3) , and chemotherapeutic agents (4) , causing cell cycle arrest or apoptosis through transcriptional regulation of its target genes. Consequently, p53 mutations and disruption of the p53 pathway are common events in the genesis of human tumors (5) . p53 stimulates the transcription of numerous genes, among them p21 (p21waf1/cip1), which encodes an inhibitor of the cell cycle (6 , 7) . Other p53 targets include bax, fas, PERP, Noxa, p53AIP1, Apaf1, and PUMA, encoding proteins that are important in apoptosis (8, 9, 10, 11, 12, 13, 14, 15) . p53 also activates the mdm2 gene, which encodes a protein that inhibits p53 function (16, 17, 18, 19) .

MDM2 is an E3 ubiquitin ligase, the last link in a complex that ubiquitinates p53, thus tagging p53 for degradation by the proteasome (20, 21, 22, 23) . The mdm2 gene is amplified in 36% of human sarcomas (24, 25, 26) , as well as in other cancers, including leukemias (27) and malignant gliomas (28 , 29) . Overexpression resulting from unknown mechanisms is also observed in a myriad of tumors (30) . Increased levels of the p53 inhibitor MDM2 in tumors suggest an alternate mechanism of inactivating p53. That MDM2 is a critical inhibitor of p53 in vivo was shown by disruption of mdm2 in the mouse. The embryonic lethality of mdm2-null mice is completely rescued by the loss of p53, indicating that the unregulated expression of active p53 is responsible for the death of mdm2-null embryos (31 , 32) .

The mdm4 gene is a new member of the mdm2 family (33) . mdm4 is amplified in some gliomas that contain wild-type p53 (34) . MDM4 also binds p53 and inhibits p53 transcriptional activation (33 , 35) . That MDM4 is a bona fide inhibitor of p53 came from studies in mice. Inactivation of mdm4 results in an embryonic lethal phenotype by 7.5 days postcoitum (dpc) that is again completely rescued by the concomitant deletion of p53 (36, 37, 38) . mdm4-/- mutant embryos die as a result of the loss of proliferative capacity. Thus, MDM4 is another important regulator of p53 during development.

Because the mdm2- and mdm4-null lethal phenotypes are p53 dependent, they offer a unique system to assay the importance of p53 downstream targets. First, the timing and mechanism of embryonic cell death in mdm2-/- mice was determined to occur at 3.5 dpc by apoptosis. This phenotype is partially rescued by loss of the p53 target bax. The p53-dependent mdm4-null proliferation defect was not rescued in the absence of p21; however, loss of p21 altered the mechanism of death from cell cycle arrest to apoptosis.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
DNA Extraction and PCR Analysis.
To determine mouse genotypes, we extracted DNA from tail biopsies. PCR analysis was performed using published primer sets for: mdm2 (31) , p53 (39) , p21 (40) , and mdm4 (36) . The primers for bax were (a) 5'-gggttgaccagagtggcgtagg-3', (b) 5'-gagctgatcagaaccatcatgg-3', and (c) 5'-acccgcttccattgctcagcgg-3',4 of which a and b amplify the wild-type allele, whereas a and c amplify the mutant allele. PCR analysis for mdm2, p53, bax, and p21 was conducted using annealing temperatures of 65°C, and PCR for mdm4 was conducted at 60°C, for 35 cycles with an extension time of 3 min.

Mouse blastocysts were digested in 1x PCR buffer (Boehringer Mannheim, Indianapolis, IN), 1 mg/ml proteinase K, and 0.1% (v/v) Triton X-100 (Sigma Chemical Company, St. Louis, MO) for 1 h at 55°C, followed by proteinase K inactivation by heating at 95°C for 5 min. The entire volume of DNA was subjected to PCR.

Histology and Immunohistochemistry.
Embryos at 5.5–9.5 dpc were fixed overnight in 10% (v/v) phosphate-buffered formalin and were embedded in paraffin. Sections, 7 µm thick, were mounted on Superfrost Plus slides (Fisher Scientific, Pittsburgh, PA) and were stained with H&E. Proliferating cell nuclear antigen (PCNA) was detected in 6.5-dpc embryos using the PCNA staining kit (Zymed Laboratories, San Francisco, CA).

Terminal Deoxynucleotidyltransferase-Mediated dUTP-Biotin Nick End Labeling (TUNEL).
Blastocysts were collected by flushing from the uterus using DMEM with 10% FCS and 1 mM HEPES. TUNEL (41) was carried out on blastocysts using the in situ cell death detection kit POD (Boehringer Mannheim, Indianapolis, IN). For older embryos, sections were treated with 20 µg/ml proteinase K for 15 min., washed, and then incubated in 3% (v/v) H2O2 in methanol for 5 min to inactivate endogenous peroxidases. After a 2-min incubation in deoxynucleotidyltransferase buffer [30 mM Tris HCl (pH 8.0), 140 mM sodium cacodylate, and 1 mM CoCl2], sections were labeled with biotin-conjugated dUTP (1:200) using terminal deoxytransferase (1:400) for 45 min at 37°C. Labeling was detected using 3,3'-diaminobenzidine (Vector Labs, Burlingame, CA).

Statistics.
The statistical significance of differences in apoptosis in blastocysts from mdm2+/- x mdm2+/- crosses was determined using the test for equality of proportions. The statistical significance of the differences in partial rescue of the mdm2-null phenotype in a bax-null background was determined using the {chi}2 test.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
To determine the mechanism of mdm2-null lethality and the role of p53 downstream genes, we first attempted to discern whether the few remaining cells in the empty decidua (5.5 dpc) were of embryonic origin. We, therefore, crossed a female mouse heterozygous for mdm2 with a Rosa 26 male mouse that carried a ubiquitously expressed ß-galactosidase gene inserted into chromosome 6 (42) . Male mice heterozygous for both ß-galactosidase and mdm2 were then crossed with female mice heterozygous for mdm2. These females were sacrificed at 5.5 dpc and the deciduae treated with 5-bromo-4-chloro-3-indolyl-ß-D-galactopyranoside (X-gal). Of 30 deciduae analyzed, 25% were empty and none contained blue-stained cells, suggesting that, at 5.5 dpc, the empty decidua is truly devoid of embryonic tissue (data not shown). One-half of the phenotypically normal embryos stained blue as a positive control.

To examine embryos earlier in development, mdm2 heterozygous mice were mated and embryos were collected at the blastocyst stage (3.5 dpc) before implantation. Of 84 blastocysts genotyped, 21 were mdm2-null (data not shown), the expected Mendelian ratio. To determine whether mdm2-null embryos demonstrated a phenotypic abnormality at this stage, we examined blastocysts microscopically, categorized them by developmental stage, and then genotyped them. Interestingly, of the 28 blastocysts analyzed in this experiment, none that were null for mdm2 had hatched (Fig. 1)Citation . Hatching is the process by which the developing embryo erupts from the zona pelucida, a membrane that surrounds the early embryo (43) . This lack of hatching suggested that the mdm2-null phenotype actually appears as early as the blastocyst stage.



View larger version (47K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Analysis of mdm2-null embryos. A, lack of hatching. Embryos from mdm2+/- x mdm2+/- crosses were categorized by developmental stage and genotyped by PCR. For apoptosis, blastocysts at 3.5 days of development were isolated and stained by terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling (TUNEL). B, a normal heterozygous blastocyst from mdm2+/+ x mdm2+/- cross. C, a blastocyst representative of 25% of those observed in a cross between mdm2+/- and mdm2+/- mice.

 
Because the mdm2-null phenotype is rescued by deletion of p53, the death of the embryo is due to unregulated p53 activity. Because p53 induces cell cycle arrest or apoptosis depending on factors such as cell type and cell cycle stage, we next determined which of these two mechanism caused mdm2-null lethality. To this end, mdm2 heterozygous mice were mated and the females sacrificed at 3.5 dpc. Blastocysts were then tested for apoptosis using the TUNEL assay, which stains the nuclei of cells committed to apoptosis. Because up to 10% of wild-type cells from a blastocyst can undergo apoptosis (44) , crosses between wild-type mice were analyzed to determine whether this apoptosis could be detected by the TUNEL assay. Of the 16 wild-type embryos tested, a maximum of 5 of the 60–70 cells in the blastocyst were TUNEL positive, indicating that the normal apoptotic number was less than 10% (Fig. 1)Citation . Of 73 blastocysts analyzed from mdm2 heterozygous crosses, 17 (23.2%) demonstrated excess apoptosis (Table 1)Citation . The affected blastocysts generally displayed a large number of apoptotic nuclei, ranging from 10 to 30 positive nuclei in any one blastocyst (Fig. 1)Citation . Several attempts were made to genotype the blastocysts after TUNEL without success. However, only the population containing mdm2-null embryos had abnormal levels of apoptosis, suggesting that the loss of mdm2 initiated a p53-dependent apoptotic cell death.


View this table:
[in this window]
[in a new window]

  		Table 1 TUNELa assay in blastocysts

Embryos from control and heterozygous crosses were analyzed at 3.5 dpc using a TUNEL assay. The frequency of apoptosis in the population of embryos containing mdm2-/- embryos was significantly greater than the frequency in the normal population (P < 0.01).

 
p53 initiates apoptosis through the activation of its downstream target genes. One of these targets, bax, is a member of the bcl-2 gene family that positively regulates apoptosis (19 , 45 , 46) . To determine whether the mdm2-null phenotype could be rescued in a bax-null background, crosses between mdm2+/- bax+/- males and mdm2+/- bax-/- females were analyzed (bax-null male mice are sterile). All of the crosses were performed in a mixed C57BL/6 and 129Sv backgrounds. From these matings, one of eight pups is expected to be null for both bax and mdm2. Of 67 mice analyzed, none were null for both genes, suggesting that the absence of bax, unlike the absence of p53, did not rescue the mdm2-null lethality.

Although the absence of bax could not fully rescue the mdm2-null lethality, the possibility remained that the absence of bax could partially rescue the phenotype. To explore this possibility, we crossed mdm2+/- bax+/- males with mdm2+/- bax-/- females and analyzed the embryos at various stages of development. Embryos at 5.5 and 6.5 dpc were too small to be accurately genotyped and, thus, were examined histologically. Of 109 deciduae examined at 5.5 and 6.5 dpc, we observed only one-half of the expected number of empty deciduae, which suggested a partial rescue of the mdm2-null phenotype (Table 2)Citation . By 7.5 dpc, we observed the expected normal:abnormal embryo ratio. At 7.5 dpc, genotypes were determined for 42 of the embryos, none of which was null for bax and mdm2 (data not shown). These data indicated that lethality in embryos that were null for both bax and mdm2 occurred between 6.5 and 7.5 dpc, instead of at 3.5 dpc as seen in embryos null for mdm2 alone.


View this table:
[in this window]
[in a new window]

  		Table 2 Partial rescue of the mdm2-null phenotype in a bax-null background

 
To determine whether these embryos were still dying by apoptosis, we performed the TUNEL assay on sections of 6.5-dpc embryos from the above cross. Of 19 embryos examined, none revealed TUNEL-positive cells. As a positive control, mouse intestine that was fixed and sectioned by the same method stained positively in the crypt cells (data not shown). If apoptosis had been the cause of lethality in the mdm2-null embryos at 6.5 dpc, two or three embryos should have been abnormal by the TUNEL assay. To assess whether mdm2-null embryos were dying by cell cycle arrest in a bax-null background, embryo sections were stained for proliferating cell nuclear antigen (PCNA), a marker for DNA synthesis. Normal embryos at 6.5 dpc were proliferating and stained strongly for PCNA (Fig. 2)Citation . Of the 28 embryos tested from a mdm2+/- bax+/- x mdm2+/- bax-/- cross, 22 stained strongly for PCNA, 5 stained only weakly, and 1 did not stain at all (Fig. 2)Citation . The number of weakly staining embryos corresponded roughly to the number of embryos expected to be null for both bax and mdm2. This weak staining may have been due to the long half-life of PCNA (47) . Maternal cells in the proliferating zone of the deciduae of all of the embryos consistently exhibited strong staining, providing an internal control for the experiment. These data suggest that cell cycle arrest and not apoptosis is the cause of mdm2-/- lethality in a bax-null background.



View larger version (191K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Sagittal sections of 6.5 dpc deciduae from wild-type crosses and from crosses between mdm2+/- bax-/- females and mdm2+/- bax+/- males. Top panels, normal embryos stained by H&E (A) or terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling (TUNEL; B), or with antibodies to proliferating cell nuclear antigen (PCNA; C). Bottom panels, abnormal embryos from a cross between mdm2+/- bax-/- females and mdm2+/- bax+/- males and represent abnormal embryos that are probably null for both mdm2 and bax, stained by H&E (D) and TUNEL (E), and with antibodies to PCNA (F). Arrows, the location of the embryo. For a positive control for TUNEL, normal mouse intestine stained strongly (not shown).

 
p53 also initiates cell cycle arrest in response to DNA damage through transcriptional activation of p21 (p21waf1/cip1). mdm4-null embryos die by cell cycle arrest in a p53-dependent manner. To determine whether the mdm4-null phenotype could be rescued by the deletion of p21, we generated mdm4+/- p21-/- mice. These mice were mated to each other and the offspring was genotyped. We expected one of four mice to be double null for p21 and mdm4. Of 57 mice analyzed, none were null for both genes. These data suggest that the mdm4 lethal phenotype cannot be rescued by the absence of p21 as it was by the absence of p53.

To determine whether a partial rescue of the phenotype occurred, mdm4+/- p21-/- mice were crossed with each other and pregnant females were sacrificed at different stages of development. Table 3Citation shows the genotyping of 8.5 and 9.5 dpc embryos. All of the abnormal embryos were mdm4-/- p21-/- (data not shown), as were mdm4-/- embryos, which suggests that no partial rescue of the mdm4-null phenotype occurred.


View this table:
[in this window]
[in a new window]

  		Table 3 Analysis of the mdm4-null phenotype in a p21-null background

 
To address the mechanism of the mdm4-/- embryo lethality in a p21-null background, we analyzed embryos at 7.5 dpc, the time at which mdm4-/- embryos show proliferative arrest. Embryo sections were stained for PCNA, and normal embryos (Fig. 3B)Citation , as well as abnormal embryos null for mdm4 and p21 (Fig. 3E)Citation , were strongly positive for PCNA, whereas mdm4-/- mutant embryos stained weakly at best (Fig. 3H)Citation . These data indicated that the mdm4-/- embryos were not dying by cell cycle arrest in the absence of p21. To determine whether mdm4-/- p21-/- embryos were dying by apoptosis, embryo sections were stained using the TUNEL assay. Normal embryos and mdm4-/- mutant embryos were negative for apoptosis (Fig. 3, C and I)Citation . However, the abnormal embryos from a cross between mdm4+/- p21-/- mice were TUNEL positive (Fig. 3F)Citation . These data indicated that in contrast to mdm4-/- embryos, mdm4/p21 double-null embryos were dying by apoptosis and not by cell cycle arrest.



View larger version (142K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Sagittal sections of 7.5-days-postcoitum (dpc) deciduae from wild-type crosses and from crosses between p21-/- and mdm4+/- mice. Top panels, normal embryos stained by H&E (A), with antibodies to proliferating cell nuclear antigen (PCNA; B), or by terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling (TUNEL; C). Middle panels, H&E (D), PCNA (E), and TUNEL (F) are abnormal embryos from crosses between mdm4+/- p21-/- mice and represent abnormal embryos probably null for both mdm4 and p21. Bottom panels, H&E (G), PCNA (H), and TUNEL (I) are abnormal embryos from a cross between mdm4+/- mice. Arrows, the location of the embryo. Dashed boxes, positive cells for PCNA (yellow) or TUNEL (red) staining.

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Loss of either mdm2 or mdm4 results in an embryo lethal phenotype as a result of deregulated expression of active p53. As such, these mouse models represent in vivo systems to dissect the importance of components of the p53 pathway. In this study, we first observed that death in mdm2-null embryos was due to apoptosis. These data have been recapitulated in tissue culture in which cells null for both mdm2 and p53 (mdm2-null cells never grow unless p53 is also missing) died by apoptosis on reintroduction of p53 (48) . Normally mouse embryo fibroblasts need to be sensitized to apoptosis by transfection with adenovirus E1A, but in this scenario, simple loss of mdm2 resulted in p53-dependent apoptosis. To determine the importance of bax, a p53 target gene, we crossed the mdm2 and bax mice to each other. Deletion of bax allowed mdm2-/- embryos to live 3 days longer and remarkably altered the mechanism of cell loss to that of proliferative arrest (the mouse phenotypes are summarized in Table 4Citation ). It is unlikely that we missed an apoptotic response in these embryos because later time points result in complete absence of an embryo.


View this table:
[in this window]
[in a new window]

  		Table 4 Phenotypes of the different mouse knockouts involved in this study

 
mdm4-null embryos, on the other hand, undergo a p53-dependent proliferative arrest during embryogenesis (36) . In our study, we showed that the lethal phenotype was not delayed by the absence of the p21, a p53 target gene that initiates cell cycle arrest (6 , 7) . However, we found that in the absence of p21, the mechanism of cell death changed from cell cycle arrest to apoptosis. These data complement findings in human tumor cell lines, showing that increased levels of p21 protect against apoptosis (49 , 50) . Therefore, p21waf1/cip1 is an important component of the p53 cell cycle arrest pathway in this in vivo model.

How does deletion of different p53 inhibitors alter the pathway chosen by p53? One possibility is that the p53 inhibitors, MDM2 and MDM4, bind different modified versions of p53. MDM2 binds a p53 poised to initiate apoptosis, and, thus, the loss of mdm2 results in that p53 initiating apoptosis. Similarly, MDM4 binds a p53 modified to initiate cell cycle arrest, and the loss of mdm4 results in proliferative arrest. This hypothesis implies that the ratio of MDM2:MDM4 determines which p53 downstream event is initiated.

The data provided in this study suggest that p53 is very versatile and that, in the absence of one of its downstream targets, it chooses another pathway. Because the promoters of bax and p21 are intact in the respective knockouts (51 , 40) , loss of p53 DNA-binding sites does not contribute to this decision. It implies a feedback mechanism in which p53 senses the lack of a cellular response and chooses another alternative. Thus, tumor cells in which wild-type p53 has been reintroduced are likely to respond by whatever mechanism to an active p53. To date, deletion of any of the known p53 targets has not halted the p53-dependent response, which suggests that p53 has multiple alternatives to achieve its ends.


   ACKNOWLEDGMENTS
 
We thank R. Behringer (University of Texas M.D. Anderson Cancer Center, Houston, TX) for Rosa 26 mice.


   FOOTNOTES
 
Grant support: In part by a Cancer Center Support Grant CA16672 and Grant CA47296 (to G. L.).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Guilermina Lozano, Department of Molecular Genetics, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: (713) 792-8945; Fax: (713) 794-4295; E-mail: gglozano{at}mdanderson.org

4 C. M. Knudson, personal communication. Back

Received 8/ 4/03. Revised 10/ 9/03. Accepted 10/17/03.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Maltzman W. a. C. L. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol. Cell. Biol., 4: 1689-1694, 1984.[Abstract/Free Full Text]
  2. Kastan M. B., Onyekwere O., Sidransky D., Vogelstein B., Craig R. W. Participation of p53 protein in cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.[Abstract/Free Full Text]
  3. Kuerbitz S. J., Plunkett B. S., Walsh W. V., Kastan M. B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA, 89: 7491-7495, 1992.[Abstract/Free Full Text]
  4. Tishler R. B., Calderwood S. K., Coleman N., Price B. D. Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents. Cancer Res., 53: 2212-2216, 1993.[Abstract/Free Full Text]
  5. Hollstein M., Sidransky D., Vogelstein B., Harris C. C. P53 mutations in human cancers. Science (Wash. DC), 253: 49-53, 1991.[Abstract/Free Full Text]
  6. El-Deiry W. S., Tokino T., Velculescu V. E., Levy D. B., Parsons R., Trent J. M., Lin D., Mercer W. E., Kinzler K. W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.[Medline]
  7. Harper J. W., Adami G. R., Wei N., Keyomarsi K., Elledge S. J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75: 805-816, 1993.[Medline]
  8. Miyashita T. R. J. C. Tumor suppressor p53 is a direct transcriptional activator of human bax gene. Cell, 80: 293-299, 1995.[Medline]
  9. Owen-Schaub L. B., Zhang W., Cusack J. C., Angelo L. S., Santee S. M., Fujiwara T., Roth J. A., Deisseroth A. B., Zhang W. W., Kruzel E. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol. Cell. Biol., 15: 3032-3040, 1995.[Abstract]
  10. Attardi L. D., Reczek E. E., Cosmas C., Demicco E. G., McCurrach M. E., Lowe S. W., Jacks T. PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family. Genes Dev., 14: 704-718, 2000.[Abstract/Free Full Text]
  11. Oda E., Ohki R., Murasawa H., Nemoto J., Shibue T., Yamashita T., Tokino T., Taniguchi T., Tanaka N. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science (Wash. DC), 288: 1053-1058, 2000.[Abstract/Free Full Text]
  12. Oda K., Arakawa H., Tanaka T., Matsuda K., Tanikawa C., Mori T., Nishimori H., Tamai K., Tokino T., Nakamura Y., Taya Y. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell, 102: 849-862, 2000.[Medline]
  13. Fortin A., Cregan S. P., MacLaurin J. G., Kushwaha N., Hickman E. S., Thompson C. S., Hakim A., Albert P. R., Cecconi F., Helin K., Park D. S., Slack R. S. APAF1 is a key transcriptional target for p53 in the regulation of neuronal cell death. J. Cell Biol., 155: 207-216, 2001.[Abstract/Free Full Text]
  14. Nakano K., Vousden K. H. PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell, 7: 683-694, 2001.[Medline]
  15. Yu J., Zhang L., Hwang P. M., Kinzler K. W., Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol. Cell, 7: 673-682, 2001.[Medline]
  16. Momand J., Zambetti G. P., Olson D. C., George D., Levine A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69: 1237-1245, 1992.[Medline]
  17. Barak Y., Juven T., Haffner R., Oren M. Mdm2 expression is induced by wild type p53 activity. EMBO J., 12: 461-468, 1993.[Medline]
  18. Perry M. E., Piette J., Zawadzki J. A., Harvey D., Levine A. J. The mdm-2 gene is induced in response to UV light in a p53 dependent manner. Proc. Natl. Acad. Sci. USA, 90: 11632-11627, 1993.
  19. Wu X., Bayle J. H., Olson D., Levine A. J. The p53-mdm-2 autoregulatory feedback loop. Genes Dev., 7: 1126-1132, 1993.[Abstract/Free Full Text]
  20. Honda R., Tanaka H., Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett., 420: 25-27, 1997.[Medline]
  21. Kubbutat M. H., Ludwig R. L., Ashcroft M., Vousden K. H. Regulation of Mdm2-directed degradation by the C terminus of p53. Mol. Cell. Biol., 18: 5690-5698, 1998.[Abstract/Free Full Text]
  22. Haupt Y., Maya R., Kazaz A., Oren M. Mdm2 promotes the rapid degradation of p53. Nature (Lond.), 387: 296-299, 1997.[Medline]
  23. Fuchs S. Y., Adler V., Buschmann T., Wu X., Ronai Z. Mdm2 association with p53 targets its ubiquitination. Oncogene, 17: 2543-2547, 1998.[Medline]
  24. Oliner J. D., Kinzler K. W., Meltzer P. S., George D. L., Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas[see comments]. Nature (Lond.), 358: 80-83, 1992.[Medline]
  25. Ladanyi M., Cha C., Lewis R., Jhanwar S. C., Huvos A. G., Healey J. H. MDM2 gene amplification in metastatic osteosarcoma. Cancer Res., 53: 16-18, 1993.[Abstract/Free Full Text]
  26. Cordon-Cardo C., Latres E., Drobnjak M., Oliva M. R., Pollack D., Woodruff J. M., Marechal V., Chen J., Brennan M. F., Levine A. J. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res., 543: 794-799, 1994.
  27. Bueso-Ramos C., Yang Y., deLeon P., Stass S. A., Albitar M. The human mdm-2 oncogene is overexpressed in leukemias. Blood, 8: 2617-2623, 1993.
  28. Reifenberger G., Liu L., Ichimura K., Schmidt E. E., Collins V. P. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res., 53: 2736-2739, 1993.[Abstract/Free Full Text]
  29. Reifenberger G., Reifenberger J., Ichimura K., Meltzer P. S., Collins V. P. Amplification of multiple genes from chromosomal region 12q13–14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. Cancer Res., 54: 4299-4303, 1994.[Abstract/Free Full Text]
  30. Evans S. C., Viswanathan M., Grier J. D., Narayana M., El-Naggar A. K., Lozano G. An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene, 20: 4041-4049, 2001.[Medline]
  31. Montes de Oca Luna R., Wagner D., Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature (Lond.), 378: 203-206, 1995.[Medline]
  32. Jones S. N., Roe A. E., Donehower L. A., Bradley A. Rescue of embryonic lethality in mdm2-deficient mice by absence of p53. Nature (Lond.), 378: 206-208, 1995.[Medline]
  33. Shvarts A., Steegenga W. T., Riteco N., van Laar T., Dekker P., Bazuine M., van Ham R. C., van der Houven van Oordt W., Hateboer G., van der Eb A. J., Jochemsen A. G. MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J., 15: 5349-5357, 1996.[Medline]
  34. Riemenschneider M. J., Buschges R., Wolter M., Reifenberger J., Bostrom J., Kraus J. A., Schlegel U., Reifenberger G. Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. Cancer Res., 59: 6091-6096, 1999.[Abstract/Free Full Text]
  35. Jackson M. W., Berberich S. J. MdmX protects p53 from Mdm2-mediated degradation. Mol. Cell. Biol., 20: 1001-1007, 2000.[Abstract/Free Full Text]
  36. Parant J., Chavez-Reyes A., Little N. A., Yan W., Reinke V., Jochemsen A. G., Lozano G. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat. Genet., 29: 92-95, 2001.[Medline]
  37. Migliorini D., Denchi E. L., Danovi D., Jochemsen A., Capillo M., Gobbi A., Helin K., Pelicci P. G., Marine J. C. Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Mol. Cell. Biol., 22: 5527-5538, 2002.[Abstract/Free Full Text]
  38. Finch R. A., Donoviel D. B., Potter D., Shi M., Fan A., Freed D. D., Wang C. Y., Zambrowicz B. P., Ramirez-Solis R., Sands A. T., Zhang N. mdmx is a negative regulator of p53 activity in vivo. Cancer Res., 62: 3221-3225, 2002.[Abstract/Free Full Text]
  39. Livingstone L. R., White A., Sprouse J., Livanos E., Jacks T., Tlsty T. D. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell, 70: 923-935, 1992.[Medline]
  40. Brugarolas J., Chandrasekaran C., Gordon J. I., Beach D., Jacks T., Hannon G. J. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature (Lond.), 377: 552-557, 1995.[Medline]
  41. Gavrieli Y., Sherman Y., Ben-Sasson S. A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol., 119: 493-450, 1992.[Abstract/Free Full Text]
  42. Friedrich G., Soriano P. Promoter traps in embryonic stem cells: a genetic screen to identify and mutate developmental genes in mice. Genes Dev., 5: 1513-1523, 1991.[Abstract/Free Full Text]
  43. Montag M., Koll B., Holmes P., van der V. Significance of the number of embryonic cells and the state of the zona pellucida for hatching of mouse blastocysts in vitro versus in vivo. Biol. Reprod., 62: 1738-1744, 2000.[Abstract/Free Full Text]
  44. El-Shershaby A. M. H. J. R. Cell redundancy in the zona-intact preimplantation mouse blastocyst: a light and electron microscope study of dead cells and their fate. Embryol. Exp. Morphol., 31: 643-654, 1974.
  45. Oltvai Z. N., Milliman C. L., Korsmeyer S. J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell, 74: 609-619, 1993.[Medline]
  46. Yin C., Knudson C. M., Korsmeyer S. J., Van Dyke T. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature (Lond.), 385: 637-640, 1997.[Medline]
  47. Bluthmann H., MacDonald-Bravo H., Bravo R. Existence of two populations of cyclin/proliferating cell nuclear antigen during the cell cycle: association with DNA replication sites. Exp. Cell Res., 173: 341-348, 1987.[Medline]
  48. de Rozieres S., Maya R., Oren M., Lozano G. The loss of mdm2 induces p53-mediated apoptosis. Oncogene, 19: 1691-1697, 2000.[Medline]
  49. Waldman T., Zhang Y., Dillehay L., Yu J., Kinzler K., Vogelstein B., Williams J. Cell-cycle arrest versus cell death in cancer therapy. Nat. Med., 3: 1034-1036, 1997.[Medline]
  50. Yu D., Jing T., Liu B., Yao J., Tan M., McDonnell T. J., Hung M. C. Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol. Cell, 2: 581-591, 1998.[Medline]
  51. Knudson C. M., Tung K. S., Tourtellotte W. G., Brown G. A., Korsmeyer S. J. Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science (Wash. DC), 270: 96-99, 1995.[Abstract/Free Full Text]
  52. Deng C., Zhang P., Harper J. W., Elledge S. J., Leder P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell, 82: 675-684, 1995.[Medline]
  53. Montes de Oca Luna R., Amelse L. L., Chavez-Reyes A., Evans S. C., Brugarolas J., Jacks T., Lozano G. Deletion of p21 cannot substitute for p53 loss in rescue of mdm2 null lethality. Nat. Genet., 16: 336-337, 1997.[Medline]



This article has been cited by other articles:


Home page
 Mol Cancer ResHome page
J. A. Barboza, T. Iwakuma, T. Terzian, A. K. El-Naggar, and G. Lozano
Mdm2 and Mdm4 Loss Regulates Distinct p53 Activities
Mol. Cancer Res., June 1, 2008; 6(6): 947 - 954.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
T. Terzian, Y.-A. Suh, T. Iwakuma, S. M. Post, M. Neumann, G. A. Lang, C. S. Van Pelt, and G. Lozano
The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss
Genes & Dev., May 15, 2008; 22(10): 1337 - 1344.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Maetens, G. Doumont, S. D. Clercq, S. Francoz, P. Froment, E. Bellefroid, U. Klingmuller, G. Lozano, and J.-C. Marine
Distinct roles of Mdm2 and Mdm4 in red cell production
Blood, March 15, 2007; 109(6): 2630 - 2633.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
H. Fan, J. Stefkova, and S. S. El-Dahr
Susceptibility to metanephric apoptosis in bradykinin B2 receptor null mice via the p53-Bax pathway
Am J Physiol Renal Physiol, September 1, 2006; 291(3): F670 - F682.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Xiong, C. S. Van Pelt, A. C. Elizondo-Fraire, G. Liu, and G. Lozano
Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development
PNAS, February 28, 2006; 103(9): 3226 - 3231.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
J. D. Grier, S. Xiong, A. C. Elizondo-Fraire, J. M. Parant, and G. Lozano
Tissue-Specific Differences of p53 Inhibition by Mdm2 and Mdm4
Mol. Cell. Biol., January 1, 2006; 26(1): 192 - 198.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chavez-Reyes, A.
Right arrow Articles by Lozano, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chavez-Reyes, A.
Right arrow Articles by Lozano, G.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online